Tactile Systems Technology 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $91.9 million, up 7.1% year over year, as lymphedema growth more than offset the expected decline in airway clearance.
- Lymphedema revenue increased 13.1% to $81.8 million, with Medicare revenue up approximately 11%, commercial revenue up approximately 17%, and VA revenue approximately flat.
- Airway clearance revenue decreased 25.1% to $10 million, reflecting DME customers taking longer than expected to work through inventory during the transition to the next-generation Aflovest system.
- Gross margin expanded 90 basis points year over year to 76.7%, while operating expenses increased 12.7% to $60.9 million.
- Net income was $7.2 million, or 31 cents per diluted share, compared with $8.2 million, or 36 cents per diluted share, in the third quarter of 2025.
- Adjusted EBITDA was $14.3 million compared with $14.4 million in the prior-year period, and adjusted EBITDA margin was 15.6% compared with 16.8%.
- Year-to-date revenue increased 12% to $252.8 million, led by 15% growth in lymphedema; year-to-date adjusted EBITDA increased approximately 35% to $29.5 million.
- The company ended the quarter with $75.1 million in cash and no outstanding borrowings, and generated $12 million in operating cash flow during the quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, ladies and gentlemen, to the third quarter 2026 earnings conference call for Tactile Medical. At this time, all participants have been placed in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session. Please note that this conference call is being recorded and will be available on the company's website for replay shortly. I would now like to turn the call over to Sam Bentzinger, Investor Relations at Gilmartin Group, for a few introductory comments.
Please go ahead. Good afternoon, and thank you for joining today's call.
With me from Tactile Medical's management team are Sheri Dodd, Chief Executive Officer, and Elaine Birkemeyer, Chief Financial Officer. Before we begin, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties. These could cause actual results to differ materially from those indicated, including those identified in the risk factor section of our annual report on Form 10-K, as well as our most recent 10-Q filing to be filed with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investor relations portion of our website. With that, I'll now turn the call over to Sheri.
Thanks, Sam. Good afternoon, everyone, and welcome to our third quarter 2026 earnings call. Here with me is Elaine Birkemeyer, our Chief Financial Officer. We delivered total revenue of $91.9 million in Q3, led by a 13% year-over-year growth in lymphedema, marking our fifth consecutive quarter of above-market double-digit growth. This consistency demonstrates the durability of our leadership position and the substantial runway created by a market that remains significantly under-penetrated. Airway clearance revenue was $10 million, down year-over-year, as anticipated, due to the one-time DME inventory transition associated with the launch of our next-generation AffloVest system. The same DME customers we highlighted in Q2 continued to work through temporary excess inventory during Q3. There were no material changes in the underlying dynamics of the business, and we continue to expect airway clearance revenue to improve sequentially in the fourth quarter.
Across the portfolio, we continue to balance strong growth in our core lymphedema business with disciplined execution. Gross margin expanded 90 basis points year-over-year in Q3 to 76.7%, contributing to Adjusted EBITDA of $14.3 million. This marks the 12th consecutive quarter of year-over-year gross margin expansion. Importantly, we have achieved this sustained improvement while continuing to invest in our product offerings to deliver greater value to patients and providers. Based on our year-to-date performance and our expectations for the fourth quarter, we are maintaining our full-year 2026 revenue guidance of $360 million to $366 million and raising our Adjusted EBITDA guidance to $50 million to $52 million. This outlook reflects our continued confidence in low double-digit growth in our business and our expectation for sequential improvement in airway clearance revenue in the fourth quarter.
We expect full-year airway clearance revenue to decline mid to high single digits year-over-year. I will now turn a closer review of our lymphedema business line, including Q3 performance and recent progress against our three strategic priorities. Elaine will then review our financial results and the outlook for the remainder of the year. Lymphedema remains our core business and primary growth. Our Q3 results demonstrate our market leadership in both basic and advanced pneumatic compression devices, with revenue growing 13% year-over-year to $81.8 million. Sequentially, lymphedema revenue grew 11%, supported by a recovery from the Medicare ordering timing disruption associated with the April implementation of prior authorization requirements. As expected, the prior authorization process has stabilized as our teams and the MACs have gained experience with the new requirements, and we believe this timing disruption is now behind us.
Medicare revenue returned to growth in Q3 of 11% year-over-year. Beyond Medicare stabilization, the quarter's performance was driven by execution across several key drivers. Our go-to-market investments in sales reps and CRM technology are extending the reach and impact of our commercial organization. Clinic visits increased 19% year-over-year in the third quarter, and referring clinics grew more than 10% year to date. These results are enabled by enhanced market insights that help our teams identify and prioritize referral opportunities across our account base. Our clinician-focused marketing programs are also delivering measurable returns, with select events generating 20% to 45% order growth from participating accounts in the 90 days following the event compared to the 90 days prior. Through our medical education team, we have educated more than 13,000 clinicians who treat lymphedema patients so far in 2026, already 25% more than in all of 2025.
This expands the number of providers equipped to identify patients and refer them to appropriate therapy. Additionally, broader patient access to advanced pumps remains durable following our tighter alignment with the NCD policy, and this is reflected in our product mix. As part of the next phase of our go-to-market playbook, this quarter we established a dedicated strategic accounts team within our broader commercial organization. This team will focus on deepening engagement with larger health systems and IDNs while expanding referral opportunities within existing high-volume regional and national accounts. Taken together, these trends give us confidence in our ability to deliver sequential lymphedema growth in Q4. We are beginning to see benefits from investments in our operating model and order process, which are improving efficiency and service quality as patients move from referral to therapy.
The strong prior year comparison next quarter resulting from the initial benefit of our alignment with the NCD will moderate year-over-year growth, but does not change our confidence in the underlying momentum of the business. Looking beyond our third quarter results, we are executing well on our three strategic priorities designed to sustain double-digit growth: expanding access to care, creating value across the patient journey, and expanding treatment options. Together, these priorities form a compelling growth model, supporting performance today while strengthening the drivers for sustained lymphedema performance over time. As with most market development opportunities, growth starts with diagnosis. Patients must first be identified, diagnosed, and referred before we can help them access clinically appropriate therapy. Expanding access to care means helping more patients get diagnosed and referred into the care pathway.
A referral is only the beginning of the order process, and growth also requires pulling a higher percentage of referrals through to shipment. Today, not every diagnosed patient with lymphedema makes it through the documentation and order process necessary to receive therapy, and each patient lost along the way is a diagnosed patient who potentially goes underserved. Creating value across the patient journey is about closing the gap and converting more eligible referrals to shipments, which is where we serve the patient and how we generate revenue. Expanding treatment options supports every step of that pathway. A broader portfolio gives clinicians more solutions for their patients, supports more additional referral opportunities, and extends the patient populations and disease stages we can serve. As these capabilities scale, we also expect greater productivity and operating leverage to support Adjusted EBITDA growth over time.
Put simply, sustained growth in our lymphedema business is not solely a function of adding sales representatives. It comes from helping more patients get diagnosed and referred, supporting more of those referrals so they can reach therapy, and expanding the range of patients and therapy needs we can address. Our first priority is expanding access to care through earlier diagnosis and broader patient coverage. The opportunity is significant. An estimated 20 million people in the U.S. are living with undiagnosed lymphedema, and many diagnosed patients continue to face coverage barriers. Our LymphaTech 3D Scanner currently gives clinicians an FDA-cleared quantitative way to measure limb volume and circumference, supporting earlier and more consistent identification of the disease. We are encouraged that LymphaTech is currently in use and generating revenue at leading academic medical centers, even ahead of an established reimbursement pathway, demonstrating its utility in clinical practice.
We recently achieved an important regulatory milestone, receiving FDA 510(k) clearance for an expanded indication of the LymphaTech 3D Scanner. LymphaTech is now cleared to provide circumference and volume measurements to aid in the assessment of lymphedema. This expands LymphaTech's clinical positioning beyond measurement and surveillance alone, and this expanded indication strengthens the foundation for our broader diagnostic strategy, including our work on clinical adoption, reimbursement, and further integrated diagnostics. On LymphaTech 3D Scanner reimbursement, our application for a Category III CPT code was discussed during our Q2 earnings call and is scheduled for final review at the February 2027 meeting. While a Category III code is a tracking code rather than a coverage decision, it is an important step towards broader reimbursement.
Together, these regulatory milestones are intended to support wider adoption of LymphaTech, enabling earlier and more objective identification of lymphedema and monitoring of fluid over time, and ultimately helping bring more patients into the care pathway. We are also making progress in broadening payer access for patients who already have been diagnosed with lymphedema. Following publication of the six-month results from our randomized control trial of Flexitouch therapy for head and neck cancer-related lymphedema, we have begun to see movement among commercial payers, with a small number removing restrictive experimental and investigational designation from their policies. Significant work remains, but these early policy changes demonstrate that our clinical evidence and payer engagement can expand coverage over time, opening access to therapy for more eligible patients and supporting additional referral opportunities. Our second priority is creating value across the patient journey.
While we see opportunities to improve the experience at every stage of care, our current focus is on the highest impact stage of the journey, helping more eligible patients successfully start therapy. By reducing friction in the upfront documentation and order process, we can improve conversion from referral to shipment and ensure more patients receive the therapy prescribed by their clinician. This benefits patients, simplifies the experience for referring clinicians and their staff, and supports a more efficient and stable operating model. Ultimately, increasing access to therapy is a key driver of both patient value and sustainable growth. During the quarter, we made organizational and operating model changes to strengthen how orders move from referral to shipment. We also continue to re-platform our end-to-end order process through our AI-enabled order management platform and care navigation work.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
